Markus von Wartburg
Education
Ph.D., economics, University of British Columbia; M.A., economics, University of Toronto; B.A., economics, Simon Fraser University
Summary of Experience
Dr. von Wartburg is currently on secondment from Analysis Group, serving as Chief Economist (T.D. MacDonald Chair in Industrial Economics) at the Canadian Competition Bureau. He will return to Analysis Group in the spring of 2024. For additional information, please contact Marissa Ginn.
Dr. von Wartburg specializes in the application of sophisticated econometric models and microeconomic theory to complex problems in antitrust, commercial litigation, media and telecommunications, finance, and intellectual property. His primary expertise is in industrial organization, antitrust and competition economics, and applied microeconomics. Dr. von Wartburg has served as an outside economic expert for Canada’s Competition Bureau, and as an expert witness on investment and competition in the telecommunications industry. He has extensive experience with horizontal and vertical merger matters in both Canada and the US, and has provided consulting support for competition authorities and merging parties. He has assisted testifying experts in engagements as diverse as the competitive assessment of single-firm conduct; the quantification of the economic impact and damages of price-fixing conspiracies; the evaluation of class certification claims in technology, health care, and financial services industries; and the estimation of damages in breach of contract and patent infringement matters. Prior to joining Analysis Group, Dr. von Wartburg lectured on strategy and game theory at the University of British Columbia.
- CRTC Review of Wholesale Wireline Services and Associated Policies
- Economic Impact of Rwandan Hospital on Its Community Is Examined Pro Bono by Analysis Group at Request of PIH
- Petition to the Governor in Council concerning Telecom Regulatory Policy CRTC 2015-326
- Toyota Industries and Cascade Corporation Transaction
-
Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution
Pediatr Pulmonol. 2012 Jan;47(1):44-52. doi: 10.1002/ppul.21521. Epub 2011 Aug 3.
2012Sawicki G, Signorovitch J, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L